The effect of probiotics on Helicobacter pylori eradication.
OBJECTIVE
Conflicting results have been reported on the effect of a variety of probiotic strains on Helicobacter pylori (HP) eradication. In this study, we evaluated the outcome of a probiotic strain composed of bacillus subtilis and Streptococcus faecium on HP eradication.


METHODS
We recruited 352 HP infected patients who were randomized into a triple-plus-probiotics group or a triple-only group; the participants received 1 week of PPI-based triple therapy with or without probiotics supplements. For the triple-plus-probiotics group, probiotics was continued for 8 weeks. All patients in the two groups were evaluated for 4 weeks after completion of therapy.


RESULTS
Using the intention to treat analysis, evaluation of the triple-plus-probiotics group showed a higher eradication rate than the triple-only group (83.5% vs. 73.3%, p=0.027). Diarrhea and overall side effects were more common in the triple-only group (p<0.05).


CONCLUSIONS
Supplementation with probiotic strains, composed of Bacillus subtilis and Streptococcus faecium, were shown to improve drug compliance, reduce side effects and enhance the intention-to-treat eradication rate of HP.
Park
Sung Keun
SK
Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Jongno-gu, Seoul 110-746, Korea.
Park
Dong Il
DI
Choi
Joong Sub
JS
Kang
Mun Su
MS
Park
Jung Ho
JH
Kim
Hong Joo
HJ
Cho
Yong Kyun
YK
Sohn
Chong Il
CI
Jeon
Woo Kyu
WK
Kim
Byung Ik
BI
D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001412:Bacillus subtilis; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016984:Enterococcus faecium; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000517:prevention & control*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole